Fucoidan

Yes — for most preparations, fucoidan is treated as a novel food in the EU. Under Regulation (EU) 2015/2283 a food not consumed to a 'significant degree' in the EU before 15 May 1997 is a novel food and requires authorisation. As of writing, the only fucoidan extracts authorised under the EU Novel Food framework are the Maritech® extracts from Marinova (Undaria pinnatifida and Fucus vesiculosus), authorised at up to 250 mg/day for the general adult population (Belgian Superior Health Council notice, 5 December 2017). Fucoidan from Cladosiphon okamuranus (Okinawa mozuku) is widely used in Japan but has not, to our knowledge, received its own EU Novel Food authorisation as an isolated ingredient — buyers planning EU distribution should secure regulatory advice and not assume blanket fucoidan acceptance.

Fucoidan is a family of sulfated polysaccharides — not a single defined molecule — and the source species materially changes the structure. Mozuku-derived fucoidan (Cladosiphon okamuranus) has been structurally characterised as having a backbone of α-1,3-linked fucose units with sulfation primarily at C-4 and a sulfate content reported around 9.8–17.6% w/w depending on the extraction. Kombu-derived (Saccharina japonica) and wakame-derived (Undaria pinnatifida) fucoidans have different branching, sulfation positions, and fucose:galactose ratios. Treat them as different ingredients on the spec sheet: at minimum, request fucose %, total sulfate %, average molecular weight (or MW distribution), and uronic-acid % per lot.

Fucoidan is sold in the US as a dietary supplement ingredient under DSHEA. Marinova's Maritech fucoidan extracts (from Undaria pinnatifida and Fucus vesiculosus) received FDA 'no questions' GRAS notification responses in 2017 (GRN 661 covers Fucus vesiculosus concentrate), making them suitable for use in conventional food categories at specified levels (typically up to 250 mg/day in supplement form, lower per-serving levels in conventional foods). For other fucoidan preparations, supplement use under DSHEA is permitted but the manufacturer carries the safety-substantiation responsibility, and food (non-supplement) use should be backed by either a self-affirmed GRAS dossier or an FDA GRAS notification.

Yes — but the claim must be tied to a specific ingredient-plus-dose combination supported by evidence submitted to the Consumer Affairs Agency (Consumer Affairs Agency, CAA). FFC is a notification system (not a pre-approval system like Tokuho/FOSHU): the producer submits the evidence dossier, and the CAA accepts the notification rather than 'approving' the product. Several mozuku-derived fucoidan FFC notifications have been accepted in Japan, including one for Okinawa mozuku fucoidan with a bowel-function-related claim. Brands considering FFC positioning need to (a) identify a specific endpoint with adequate clinical evidence, (b) build their own systematic-review-backed dossier, and (c) note that the IP and dosing of the underlying clinical evidence may constrain who can credibly file.